Thank you for participating in the Multidisciplinary Treatment Planning Survey for the NCI Community Cancer Centers Program (NCCCP). This survey is being conducted by the National Cancer Institute (NCI) to understand how NCCCP sites conduct multidisciplinary treatment planning, a feature of multidisciplinary care, and to gain insight into the variety of ways it is structured and implemented for different types of cancers.
This survey is designed to solicit information about the multidisciplinary treatment planning services being planned for <b>breast cancer</b> patients at your facility. This cancer was chosen because your facility has reported multidisciplinary care experience in this area. This survey is intended to obtain information at the <b>organizational</b> level and not at the physician or specialty level.
As the Quality of Care Lead at your facility, you have been identified as the most appropriate respondent to complete this survey. We encourage you to consult with other colleagues at your Cancer Center to accurately respond to these questions. There are no right or wrong answers. Your responses will help expand existing knowledge of multidisciplinary treatment planning for cancer and inform future research in cancer care delivery.

### **Burden Statement and Consent Page**

OMB No.: 0925-XXXX

Expiration Date: xx/xx/20xx

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-XXXXX). Do not return the completed form to this address.

Your participation in this study is voluntary. You can decide not to be in the study, and that will not affect your status in the NCCCP. You will not receive an incentive to participate in the study.

Your privacy is very important to us. Your name and facility will not be linked to your answers & will not show up on any reports about this study. Instead, a code number will be assigned to your survey. Your responses will be kept secure to the extent provided by law and will only be accessible to the study team. All responses will be reported in aggregate.

Although your participation in this research may not benefit you personally, it will help us understand how NCCCP sites conduct multidiscplinary treatment planning.

There are no risks to individuals or organizations participating in this survey.

If you have questions about this study or to opt out, please contact Lead Investigator, Dr. Irene Prabhu Das at 240-276-6799 or prabhudasi@mail.nih.gov. If you have any questions about your rights as a participant in this study or any concerns or complaints, please contact the National Cancer Institute's OMB Project Clearance Liaison at 301-480-0541 or horovitchkellv@mail.nih.gov.

I have read and understand the above information. By clicking the "Next" button below, I consent to participate voluntarily in this survey.

### **Survey Instructions**

Please review ALL the instructions before beginning the survey.

For purposes of this survey, multidisciplinary treatment planning is described as a coordinated approach that brings together multiple cancer specialists as well as other clinicians and professionals to plan the appropriate treatment and other integral services for a cancer patient once a confirmed diagnosis is made (e.g., through surgery or biopsy). Therefore, multidisciplinary treatment planning occurs before initiating the required complex, multi-modality therapies.

- It is important that you consult with colleagues at your Cancer Center if you are unable to answer questions that may be administrative in nature and/or may not apply to your specialty. You may choose to print and share the survey to obtain the responses to some or all of the questions. Once you obtain the responses you need, you can then **complete the survey online. No written surveys will be accepted.**
- If your facility has a formal written policy, standard operating procedures, or a performance evaluation tool for multidisciplinary care (other than the NCCCP MDC Assessment Tool), please obtain access to them in advance to help complete the survey.
- We encourage you to answer all of the questions so that we can best understand multidisciplinary treatment planning at your facility and adequately represent it in the survey results.
- Your responses will be kept secure to the extent provided by law. Final results will not identify your facility site. Only aggregate results of this survey will be used. Neither you nor your facility will be linked to the final results.
- The survey should take no more than one hour to complete. This includes time to consult with your colleagues and team to respond to the survey questions. Your responses will be saved as you complete the survey. You do not have to complete the survey in one sitting. However, please save this web link used to access the survey, as you will need to click on the link again to access the survey if you chose to complete it at another time.

# A. OVERVIEW OF MULTIDISCIPLINARY TREATMENT PLANNING FOR CANCER CARE

For the following questions, please think about typical breast cancer cases at your Cancer Center.

For purposes of this survey, **multidisciplinary treatment planning** is defined as a coordinated approach that brings together multiple cancer specialists as well as other clinicians and professionals to plan the appropriate treatment and other integral services for a cancer patient once a confirmed diagnosis is made (e.g., through surgery or biopsy). Therefore, multidisciplinary treatment planning occurs before initiating the required complex, multi-modality therapies.

1. Please choose the statement that best describes how the treatment planning approach
for breast cancer patients at your facility compares with the survey's definition of
multidisciplinary treatment planning.

multidisciplinary treatment planning.
C The survey definition of multidisciplinary treatment planning exactly describes the treatment planning approach for breast cancer patien at my facility.
C The survey definition of multidisciplinary treatment planning describes some but not all aspects of the treatment planning approach for breast cancer patients at my facility.
C The survey definition of multidisciplinary treatment planning does not at all describe the treatment planning approach for breast cancer patients at my facility.
Other (please specify)

# 2. What is the multidisciplinary treatment planning approach for breast cancer patients called at your facility?

0	Multidisciplinary Conference
	Multidisciplinary Contelence
0	Multidisciplinary Clinic
0	Multidisciplinary Team
0	Tumor Board
0	Tumor Conference
0	Cancer Conference
0	Other (please specify)

ing meetings for
990

5. Are breast cancer patients <u>typically</u> invited to attend treatment planning meetings with the multidisciplinary cancer care team?	
C Yes	
C No	

6. V	Vhy are patients not invited? (CHECK ALL THAT APPLY)
	Medical providers would not be able to speak as freely in the presence of the patient.
	Our facility lacks the infrastructure to accommodate patient attendance.
	It is an inefficient use of time to include the patient.
	There are concerns about legal liability/accountability for decisions regarding a patient's treatment.
	The discussion may be too overwhelming or confusing for the patient.
	Medical providers aren't able to bill for time spent with patients in these discussions.
	There are concerns that inviting patients may compromise the privacy of their health information.
	Other (please specify)

7. Which best describes the physicians that participate in multidisciplinary treatment planning discussions about breast cancer patients at your facility?	
0	They are all private practice physicians.
0	They are mostly private practice physicians.
0	They are an even mix of private practice physicians and physicians employed by this facility.
0	They are mostly physicians employed by this facility.
0	They are all physicians employed by this facility.
0	Other (please specify)
8. [	Does your Cancer Center have a formal written policy or standard operating procedures
	providing multidisciplinary treatment planning?
0	Yes
0	No
0	Under development

9. Would your facility be willing to share a copy of your Cancer Center's policy or standard operating procedures?	
0	Yes (The researchers will contact you)
0	No
0	I don't know

This section asks questions about multidisciplinary treatment planning meetings and initial case presentations for <b>breast cancer</b> patients at your Cancer Center.
10. Are multidisciplinary treatment planning meetings for breast cancer cases held on a set
schedule or only as needed?
C Set schedule
C As needed
© Both
11. Is there a formally designated person(s) or position(s) that coordinates multidisciplinary treatment planning meetings for breast cancer?
C Yes
O No

12. Who is responsible for <u>coordinating</u> multidisciplinary treatment planning meetings? (CHECK ALL THAT APPLY)	
	Nurse
	Patient/Nurse Navigator
	Tumor/Cancer Registrar
	Tumor Conference Administrative Coordinator
	Clinic Nursing Staff
	Physician
	Nurse Practitioner/Physician Assistant
	Other (please specify)

13. Is there a dedicated space for multidisciplinary treatment planning meetings for breast cancer cases?
C Yes
C No
14. <u>Prior to the initial presentation</u> for breast cancer cases, is information provided to the multidisciplinary treatment planning team?
C Yes
O No
C Sometimes

assessment tool  Open clinical trials  Consults  Other	List of physicians involved	List of physicians involved	List of physicians involved		All team members	Core team members only (Medical Oncologist, Radiation Oncologist, Surgeon or Surgical Oncologist, Pathologist, Radiologist)	Other additional team members
PET/CT and other radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	PET/CT and other radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	PET/CT and other radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	PET/CT and other radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Meeting agenda			
radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Consults  Consults  Other	radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	radiology films and reports  Clinician dictations or notes  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Consults  Consults  Other	List of physicians involved			
Out-patient records  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Nout-patient records	Out-patient records  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Nout-patient records  Out-patient records  Diagnostic test results  Pathology results/slides  History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other				
Diagnostic test results	Diagnostic test results	Diagnostic test results	Diagnostic test results				
Pathology results/slides	Pathology results/slides	Pathology results/slides	Pathology results/slides	Out-patient records			
History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	History and physical (most recent or comprehensive)  Family history  Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Diagnostic test results			
recent or comprehensive)  Family history	Pathology results/slides						
Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Genetic testing results  Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other				
Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Guidelines (e.g. NCCN, NQF, ASCO)  Adjuvant! Online assessment tool  Open clinical trials  Consults  Other	Family history			
NQF, ASCO)  Adjuvant! Online	Genetic testing results						
Open clinical trials  Consults  Other							
Consults   Other	Consults   Other	Consults   Other	Consults   Other	•			
Other	Other	Other	Other	Open clinical trials	П		
				Consults			
Other (please specify)	Other (please specify)	Other (please specify)	Other (please specify)	Other			
				Other (please specify)			

	Does your facility have guidelines indicating when the initial case presentation should scheduled once cancer is diagnosed?
0	Yes
0	No
0	Under development
	Would your facility be willing to share a copy of your initial case presentation delines?
0	Yes (The researchers will contact you)
0	No
0	Don't know
	Once patients have a confirmed breast cancer diagnosis, who decides if the case eds to be presented? (CHECK ALL THAT APPLY)
	Medical Oncologist
	Surgical Oncologist
	Radiation Oncologist
	General Surgeon
	Site-Specific Cancer Specialist
	Pathologist
	Nurse Practitioner/Physician Assistant
	Patient/Nurse Navigator
	No one person or role decides, any team member can present a case
	No one person or role decides, all cases presented
	Other (please specify)

# SURVEY ON MULTIDISCIPLINARY TREATMENT PLANNING FOR 19. When is the initial case presentation for confirmed cancer cases typically held? After definitive cancer diagnosis and before multi-modality therapy is initiated Sometime after multi-modality therapy is initiated A mixture of both C Some other time (please specify)

	Which care providers are expected to attend the initial case presentation of breast
can	cer cases? (CHECK ALL THAT APPLY)
	Medical Oncologist
	Surgical Oncologist
	Radiation Oncologist
	Site-Specific Cancer Specialist
	Primary Care Physician
	Surgeon (General and Specialty)
	Pathologist
	Radiologist
	Palliative Care Specialist
	Clinic Nurse
	Clinical Trials Nurse/Research Nurse/Clinical Research Associate
	Nurse Practitioner/Physician Assistant
	Social Workers
	Psychologist
	Patient/Nurse Navigator
	Genetic Counselor
	Tumor/Cancer Registrar
	Primary Care Physician
	Clergy
	Dietitian
	Speech, Occupational, or Physical Therapist
	Other Provider (please specify)

providers are not able to	participate <sup>2</sup>	?		
es				
0				
ometimes (please indicate what this de	epends on)			
		_		
		~		

	How frequently does the primary care physician, that is, general internist and family ctice physician, attend initial case presentations for breast cancer patients?
0	Never
0	Rarely
0	Sometimes
0	Often
0	Always
	When care providers convene for the initial case presentation for breast cancer ients, how do they usually attend?
0	All in person
0	All teleconference/Conference Call
0	All virtual (Computer-based i.e. video-conference, Telemedicine, etc.)
0	A mix of in-person and teleconferencing
0	A mix of in-person and virtual
0	A mix of in-person, teleconferencing, and virtual
24.	How often is attendance taken at initial case presentations?
0	Never
0	Rarely
0	Sometimes
0	Often
0	Always

25.	What information is presented at initial case
AP	PLY)
	Meeting agenda
	List of physicians involved
	PET/CT and other radiology films and reports
	Clinician dictations or notes
	Out-patient records
	Diagnostic test results
	Pathology results/slides
	History and physical (most recent or comprehensive)
	Family history
	Genetic testing results
	Guidelines (e.g., NCCN, NQF, ASCO)
	Adjuvant! Online assessment tool
	Open clinical trials
	Consults
	Other (please specify)
	After the multidisciplinary treatment planning on discussed, how are treatment decisions/red
0	By a vote by the team members.
0	By one person on the team (i.e. treating physician, medical oncologis
0	In consultation with the patient and/or family
0	Decisions are made in some other way (please specify)

### **C. CLINICAL TRIALS**

	ext few questions are about how determination of clinical trials eligibility fits into multidisciplinary treatment planning for <b>breast cancer</b> nts at your Cancer Center.
	How often is screening for clinical trial eligibility done <u>prior to the initial case</u> <u>sentation</u> for breast cancer patients?
0	Never
0	Rarely
0	Sometimes
0	Often
0	Always
	When are clinical trial options for breast cancer patients <u>typically</u> discussed among the Itidisciplinary treatment planning team?
0	Prior to the initial case presentation
0	At the time of the initial case presentation
0	Prior to initiation of first line treatment
0	After proceeding with standard therapy
0	Other (please specify)
eliç	How does the multidisciplinary team for breast cancer typically assess patient gibility for clinical trials? (Who is involved, what information is presented, tools used, any additional information regarding the process)

### **D. PATIENTS & MULTIDISCIPLINARY TREATMENT PLANNING**

These next questions are about patient involvement in multidisciplinary treatment planning. Please continue to think about **typical breast cancer** cases that require multi-modality therapies once a definitive cancer diagnosis has been made.

cases	ases that require multi-modality therapies once a definitive cancer diagnosis has been m	ade.
	30. Prior to the initial case presentation, how often does	
pat	patients with information about multidisciplinary treatm	ent planning?
0	C Never	
0	C Rarely	
0	O Sometimes	
0	C Often	
0	O Always	
0	C Other (please specify)	

	How are breast cancer patients informed about the multidisciplinary treatment nning? (CHECK ALL THAT APPLY)
	We provide written communication to the patient summarizing the approach.
	Interpreter services are provided as needed to explain the approach.
	A dedicated nurse/patient navigator discusses with patient.
	The physician discusses with patient.
	Other (please specify)
	Who usually invites breast cancer patients to attend the initial case presentation? IECK ALL THAT APPLY)
` □	Not Applicable, patients are not invited to attend
	Nurse
	Patient/Nurse Navigator
	Clerical Staff
	Social Worker
	Physician
	Nurse Practitioner/Physician Assistant
	Other (please specify)

33.	When are breast cancer patients invited to attend? (CHECK ALL THAT APPLY)
	At the initial consult appointment
	After the initial consult by phone
	After the initial consult at a subsequent appointment
	Some other time (please describe)

How often do breast cancer patients attend the initial case presentation?
Never
Rarely
Sometimes
Often
Always

	For those breast cancer patients who are invited but do not attend, what are some of reasons? (CHECK ALL THAT APPLY)
	The patient is not feeling well enough.
	The patient feels overwhelmed with diagnosis/medical system.
	The patient is concerned about hearing things that will upset them.
	The patient feels the medical team is responsible for making treatment decisions.
	The time/location of the meeting is inconvenient for the patient.
	Some other reason (please specify)
	Are breast cancer patients welcomed to invite their family members to attend the initial seepresentation?
	Yes
0	No
	What information about the initial case presentation is shared with breast cancer ients who do not attend the presentation? (CHECK ALL THAT APPLY)
	Meeting date and time
	List of attendees
	Treatment plan
	Summary (verbal or written) of the meeting
	Recommendations from the treatment planning meeting
	No information is shared
	Other (please specify)

For th	
••	lese next two questions, please think about all breast cancer patients, whether or not they attended the initial case presentation.
38.	Who follows up with breast cancer patients after the initial case presentation? (CHECK
ALI	L THAT APPLY)
	Nurse
	Patient/Nurse Navigator
	Clerical Staff
	Social Worker
	Physician
	Nurse Practitioner/Physician Assistant
	No one follows up
	Someone else (please specify)
30	How does follow-up typically occur? (e.g. in writing, by telephone, in-person
	cussion, patient portal, etc.) Please describe.
uis	
40	
4U-	How soon after the initial case presentation for breast capear nationts does the follow
	How soon after the initial case presentation for breast cancer patients does the follow-
up	typically occur?
up '	typically occur?  The same day
<b>up</b> •	typically occur?  The same day  1 day after
o o	The same day  1 day after  2-3 days after
o o	The same day  1 day after  2-3 days after  4-7 days after
o o o	The same day  1 day after  2-3 days after  4-7 days after  8-14 days after
o o o	The same day  1 day after  2-3 days after  4-7 days after  8-14 days after  15 days or more
o o o o o	The same day  1 day after  2-3 days after  4-7 days after  8-14 days after  15 days or more  No follow-up occurs
o o o	The same day  1 day after  2-3 days after  4-7 days after  8-14 days after  15 days or more
o o o o o	The same day  1 day after  2-3 days after  4-7 days after  8-14 days after  15 days or more  No follow-up occurs

This section asks about multidisciplinary treatment planning after the initial case presentation. Please continue to think about typical breather the initial case presentation.	ast
cancer cases that require multi-modality therapies once a definitive cancer diagnosis has been made.	

cancer cases that require multi-modality therapies once a definitive cancer diagnosis has been made.		
After the initial case presentation, does the multidisciplinary team for breast cancer		
ients meet to modify the current treatment plan?		
Never		
Rarely		
Sometimes		
Often		
Always		
Other (please specify)		

42. For the breast cancer cases already discussed, what are the reasons for modifying the current treatment plan? (CHECK ALL THAT APPLY)	
	Disease has progressed
	Patient is unable to tolerate/maintain current treatment plan
	Second primary is diagnosed
	Patient has a co-morbid condition
	Patient is experiencing poor symptom management
	Need to assess clinical trial options
	Pathology and imaging are discordant
	Case demonstrates more advanced disease than originally anticipated
	Patient refuses recommended treatment
	Other (please specify)
	Do additional specialists, who were not part of the initial case presentations, ever
	Do additional specialists, who were not part of the initial case presentations, ever ticipate in subsequent meetings about those breast cancer cases?
par	ticipate in subsequent meetings about those breast cancer cases?
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes
par o	ticipate in subsequent meetings about those breast cancer cases?  Yes

44. Which specialists or other professionals, who were not part of the initial case presentation, have participated in subsequent meetings about breast cancer cases? (CHECK ALL THAT APPLY)	
	Site-Specific Cancer Specialist
	Primary Care Physician
	General Surgeon or Surgical Specialist
	Pathologist
	Palliative Care Specialist
	Clinic Nurse
	Clinical Trials Nurse/Research Nurse/Clinical Research Associate
	Nurse Practitioner/Physician Assistant
	Social Worker/ Psychologist
	Patient/Nurse Navigator
	Genetics Counselor
	Clergy
	Dietitian
	Speech, Occupational, or Physical Therapist
	Pain Management Specialist
	OBGYN
	Other (please specify)
	e following questions, please think about your entire multidisciplinary care process for breast cancer cases not just the multidisciplinary nent planning meeting.
trea ind	A treatment plan is a comprehensive, formal plan prospectively outlining anticipated atment approaches. Is a comprehensive, formal treatment plan <u>typically</u> developed for ividual breast cancer patients?  Yes No

46. Do breast cancer patients <u>typically</u> receive a copy of the comprehensive, formal treatment plan?	
0	Yes
0	No
0	Other (please specify)
47.	Is a copy of the comprehensive, formal treatment plan <u>typically</u> included in the patient's
me	dical record?
0	Yes
0	No
0	Other (please specify)
48.	Do primary care physicians typically receive a copy of the comprehensive, formal
	atment plan?
0	Yes
0	No
0	Other (please specify)
	A treatment summary retrospectively summarizes the treatments that the patient has eived. Is a treatment summary <u>typically</u> developed?
0	Yes – A comprehensive summary of all cancer treatments is developed (includes radiation, chemotherapy, and/or surgery)
C cher	Yes – A treatment-specific summary is developed where only some treatments are documented (e.g. only radiation therapy or only notherapy is documented)
0	No treatment summary is developed

50. Do breast cancer patients <u>typically</u> receive a copy of either the comprehensive treatment summary or the treatment-specific summary?	
0	Yes
0	No
0	Other (please specify)
	Does the referring physician <u>typically</u> receive a copy of either the comprehensive
	atment summary or treatment-specific summary?
0	Yes
0	No
car	If the referring physician is not the patient's primary care physician, does the primary e physician typically receive a copy of either the comprehensive treatment summary or treatment-specific summary?
0	Yes
0	No
0	Not Applicable (if the referring physician is the patient's PCP)

### F. MULTIDISCIPLINARY TREATMENT PLANNING INFRASTRUCTURE

nu	What type of medical records system is used to support the provision of Itidisciplinary treatment planning for breast cancer patients?
0	Paper chart
0	Electronic Medical Record (EMR)
0	Mixture of paper and EMR
0	Other (please specify)
ıu	From which departments can results/reports be accessed in preparation for the Itidisciplinary treatment planning meetings about breast cancer cases? (CHECK AL AT APPLY)
	Laboratory
	Radiology
	Radiation Oncology
	Pharmacy
	Medical Oncology
	Nuclear Medicine
	Surgery
	Pathology
	Nursing
	Clerical Staff
	Other (i.e. other hospital departments and/or private practice physician records). Please specify.

### F. MULTIDISCIPLINARY TREATMENT PLANNING INFRASTRUCTURE

55. An "integrated" medical records system is one in which patient data within the hospital can be linked or shared with a physician or practice/clinic at another location that sees the same patient. In your opinion, how integrated is the medical records system that supports multidisciplinary treatment planning for breast cancer cases at your facility?	
0	Not at all integrated
0	Somewhat integrated
0	Fully integrated
0	Other (please specify)
56.	At this facility, are private practice physicians monetarily compensated for their time in
mu	Itidisciplinary treatment planning meetings for breast cancer cases?
0	Yes
0	No
0	Don't know

# SURVEY ON MULTIDISCIPLINARY TREATMENT PLANNING FOR F. MULTIDISCIPLINARY TREATMENT PLANNING INFRASTRUCTURE 57. How are private practice physicians monetarily compensated for attending the multidisciplinary treatment planning meetings for breast cancer? (e.g. consultation charge through patient's insurance, fee negotiated with hospital, etc.) Please describe.

### F. MULTIDISCIPLINARY TREATMENT PLANNING INFRASTRUCTURE

58. Are non-financial incentives provided to private practice physicians in exchange for provision of multidisciplinary treatment planning for breast cancer?	
C Yes	
C No	

### F. MULTIDISCIPLINARY TREATMENT PLANNING INFRASTRUCTURE

59. What are the non-financial incentives? (CHECK ALL THAT APPLY)	
	Hospital privileges
	Research staff support
	Support with credentialing
	Continuing Medical Education credits or units
	Conference registration and/or travel fees
	Marketing and promotion of multidisciplinary care provision
	Cancer Center membership
	Meals provided
	Other (please specify)

### G. ASSESSMENT OF MULTIDISCIPLINARY TREATMENT PLANNING

<u> </u>	
These	next few questions are about the evaluation of multidisciplinary treatment planning at this facility.
60.	Does your Cancer Center evaluate the performance of multidisciplinary treatment
pla	nning for breast cancer? (Please exclude the use of the MDC Assessment tool.)
0	Yes
0	No
0	Other (please specify)

### G. ASSESSMENT OF MULTIDISCIPLINARY TREATMENT PLANNING

planning for breast cancer? (CHECK ALL THAT APPLY)  Frequency of meetings	
Frequency of meetings	
☐ Timeliness to treatment	
☐ Use of clinical and pathological staging variables to confirm staging	
Use of a physician "agreement of participation" to determine membership	
☐ Use of clinical guidelines to develop treatment plan	
☐ Minimum percent of patient participation in clinical trials	
☐ Screening for clinical trial eligibility	
☐ Clinical trials offered to eligible patients	
Clinical trial enrollment of eligible patients	
☐ Patient satisfaction with the recommended treatment plan	
☐ Do not evaluate	
☐ Other (please specify)	

### G. ASSESSMENT OF MULTIDISCIPLINARY TREATMENT PLANNING

62. Would your facility be willing to share a copy of your evaluation documents (excluding the MDC Assessment tool)?		
C Yes (A researcher will contact you)		
O No		
C Don't know		
63. How does the Cancer Center utilize the MDC Assessment tool?		

SURVEY ON MULTIDISCIPLINARY TREATMENT PLANNING FOR		
H. ADDITIONAL THOUGHTS ABOUT MULTIDISCIPLINARY TREATMENT PLANNING		
64. Is there anything else about multidisciplinary treatment planning that you would like to share?		

### I. CLOSING QUESTIONS

65. Please indicate which of these reflects yo	ur experience in responding to the survey
questions:	

que	estions:
0	I answered the questions on my own without consulting anyone.
0	I consulted with the other colleagues in the Cancer Center before I responded to the questions.
0	I requested someone else to answer the questions.
0	I worked with another person to complete the survey together.
66.	What is your specialty?
0	Medical Oncologist
0	Surgical Oncologist
0	Radiation Oncologist
0	Surgeon
0	Pathologist
0	Radiologist
0	Registered Nurse
0	Other Cancer Specialist or Medical Specialty (please specify)
67.	Are you employed by your Cancer Center or in private practice?
0	Cancer Center only
0	Private practice only
0	Both
0	Other (please specify)

68.	Please indicate your cancer center's current CoC accreditation cancer program
cat	egory.
0	Academic Comprehensive Cancer Program
0	Community Cancer Program
0	Comprehensive Cancer Program
0	Integrated Network Cancer Program
0	Other (please specify)
69.	What is your cancer center's annual case volume for the most recent year?
70.	Please identify the total number of licensed beds in the hospital affiliated with the
NC	CCP site.

# SURVEY ON MULTIDISCIPLINARY TREATMENT PLANNING FOR THANK YOU FOR TAKING THE TIME TO COMPLETE THIS SURVEY. Your responses will be very helpful in understanding multidisciplinary care within the NCCCP. Please review or double check your responses prior to clicking the "Done" button. Once you click "Done" you will not be able to log back into the survey. Please click "Done" when you are ready to submit your answers.